Establishment of cerebral embolic stroke treatment by Staphylokinase
| Project/Area Number |
26462149
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Hirosaki University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | Staphylokinase / Cerebral infarction / Embolic stroke / スタフィロキナーゼ / 脳塞栓症 / 脳梗塞 / 脳浮腫 / 脳卒中 |
|---|
| Outline of Final Research Achievements |
Four hundred microgram per kg Staphylokinase (SAK) reduced cerebral infarction same as clinical dose of t-PA. The rate of respiratory trouble and mortality in SAK groups were significantly smaller than t-PA group. Reduction of MMP-9 and preservation of blood brain barrier were detected. And intra-arterial injection of VEGF antagonist significantly reduced cerebral infarction volume and preserve neural function. Reduction of IP3KA and Occludin were detected. High dose SAK is an alternative to t-PA in the treatment of embolic ischemic stroke. Combination therapy of SAK and VEGF antagonist achieved synergism in ischemic stroke treatment.
|
Report
(4 results)
Research Products
(10 results)
